Is RF microneedling still profitable for med spas in 2024?

Yes—InMode's Q2 earnings beat shows steady U.S. demand, high per-treatment margins, and minimal reimbursement friction. RF microneedling remains a workhorse modality with strong patient demand, though you'll need to benchmark device costs and break-even patient volume against competitors like Cutera, Lumenis, and Candela.

How many RF microneedling devices do I need to break even?

Break-even patient volume varies by device cost, treatment pricing, and local competition. InMode's installed-base economics show the company drives recurring revenue through procedure volume, but you should calculate your specific ROI based on your capex, lease terms, and target patient throughput before committing.

Should I buy InMode or lease it?

Evaluate both options against your cash flow and growth timeline. InMode's strong market position supports resale value if you buy, but leasing preserves capital and lets you upgrade faster if competitive RF platforms with lower capex or faster ROI emerge.

What's driving InMode's Q2 earnings beat?

Steady U.S. demand for RF microneedling and radiofrequency platforms, combined with a resilient installed base generating recurring revenue. InMode beat earnings estimates by $0.02 per share and topped revenue expectations despite competitive saturation in the RF microneedling market.

How competitive is the RF microneedling market right now?

The field has densified significantly, with major players including Cutera, Lumenis, and Candela competing alongside InMode. Device acquisition cost and break-even patient volume are now critical differentiators—newer entrants may offer lower capex or faster ROI, so compare total cost of ownership before purchasing.

Devices & Tech

InMode Q2 Beats on Steady U.S. Device Demand

Earnings topped estimates; U.S. market holding despite competitive RF microneedling saturation.

By Evan at Inside MedSpa · Aug 6, 2026

1-YEAR MOVE

INMD ▲1.0%

1-year price move by ticker
Ticker	Company	1-year change
INMD	InMode Ltd.	+1.0%

InMode beat Q2 earnings expectations by $0.02 per share and topped revenue estimates on steady U.S. demand for its RF microneedling and radiofrequency platforms. The company's core U.S. installed base continues to drive recurring revenue and procedure volume.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/inmode-q2-beats-steady-us-demand/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

InMode Q2 Beats on Steady U.S. Device Demand

Share

Discussion

Leave a comment

By the time it's news, it's too late.